London (PRWEB) September 19, 2013
This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million.
The report provides separate comprehensive analytics for the US, Europe, and Rest of World.
Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets.
The report profiles 35 companies including Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp., Ceregene, Inc., Cortex Pharmaceuticals, Inc., Intellect Neurosciences Incorporation, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp., Teva Pharmaceutical Industries Ltd., Trophos SA, Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Huntington’s Disease - Few Quick Facts II-1
Market Opportunity II-2
Competition in the Global HD Therapeutics Market is Nonexistent II-3
Effectiveness of Current HD Management Strategies II-3
HD Treatment and Drugs II-4
Alternative Treatment Approaches for Huntington’s disease II-5
Alternate Approaches and Therapies II-5
Off-Label Prescriptions II-5
Select Off-Label Drugs Prescribed for Huntington’s Disease II-6
2. HD THERAPEUTICS MARKET TRENDS II-7
Companies Boost R&D Spending for HD Therapeutics II-7
Improved Diagnostics Fueling Intere
Copyright©2012 Vocus, Inc.
All rights reserved